My watch list
my.bionity.com  
Login  

BioNTech receives USD 325 million

One of the largest private EU biotech funding events expands global shareholder base

10-Jul-2019

QuinceMedia, pixabay.com, CC0

BioNTech Raises USD 325 Million in an Upsized Series B Financing to Further Advance Individualized Immuno-Oncology Pipeline (symbolic picture).

BioNTech SE announced the completion of a USD 325 million Series B financing round, making it one of the largest single private funding rounds for a biotechnology company in European history. The fund raising was upsized and was led by Fidelity Management & Research Company with participation from both new and existing investors, including Redmile Group, Invus, MiraeAsset Financial Group, Platinum Asset Management, Jebsen Capital, Steam Athena Capital, BVCF Management and the Struengmann Family Office. Two-thirds of the funding came from new investors. The proceeds of the financing will support the continued advancement of BioNTech’s therapeutics pipeline and manufacturing infrastructure.

“BioNTech has executed on a highly disruptive business strategy that aims to change the treatment paradigm for cancer patients,” said Helmut Jeggle, Chairman of BioNTech. “We value the continued participation of our existing investors and welcome new investors to this powerful global syndicate representing North America, Asia and Europe.”

Prof. Ugur Sahin, CEO and Co-Founder of BioNTech added: “This financing round is a significant milestone that recognizes our scientific and initial clinical track record to date. With our ongoing focus on bringing together transformative technologies, it is exciting to have the support from high-technology investors who see the accelerating convergence of biology with bioinformatics, robotics and artificial intelligence as an opportunity to develop more precise, efficacious and cost-effective individualized immunotherapies.”

The funding follows the Series A financing of USD 270 million announced in January 2018, led by Redmile Group. The previous financings have enabled BioNTech to advance a pipeline of seven product candidates in eight ongoing clinical trials, to establish a second GMP manufacturing license for production of its individualized neoantigen specific immunotherapies and to expand its antibody platform, most recently, through the acquisition of a Phase I/IIa program against pancreatic cancer from MabVax Therapeutics Inc. In conjunction with the MabVax Therapeutics acquisition of assets, the company has also recently established its US research and development facility in San Diego, California.

Facts, background information, dossiers
More about BioNTech
  • News

    Sanofi Invests EUR 80m in BioNTech

    BioNTech AG announced that it has extended its research collaboration with Sanofi initiated in late 2015 and Sanofi is investing* EUR 80 million (approximately USD 91.5 million) in equity in BioNTech. Simultaneously BioNTech has entered into an agreement with Sanofi to co-develop the first ... more

    BioNTech Secures USD 270 Million in Series A Financing

    BioNTech AG announced it has completed a USD 270 million Series A round of financing. The Company previously completed a seed round fundraising in 2008 concurrent with its founding. The Series A round was led by the Redmile Group and joined by Janus Henderson Investors, Invus, Fidelity Mana ... more

    Sanofi and BioNTech announce collaboration

    Sanofi and BioNTech A.G. announced that they have entered into a multiyear exclusive collaboration and license agreement. This research collaboration between Sanofi and BioNTech will leverage the scientific expertise of the two organizations to discover and develop up to five cancer immunot ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE